

87. (new) The recombinant vector according to claim 67, with said vector being characterized as a live recombinant vector.

88. (new) The recombinant vector according to claim 67, wherein said vector is a vaccinia virus vector.

89. (new) The recombinant vector according to claim 88, wherein said vector is avipox.

90. (new) The recombinant vector according to claim 88, wherein said vector is Ankara Modified Virus (AMV).

91. (new) The recombinant vector according to claim 67, wherein said vector is a baculovirus vector.

92. (new) A recombinant E1 and/or E2 and/or E1/E2 protein according to claim 81, further characterised in that said host cells are mammalian cells, infected with recombinant vaccinia virus.

93. (new) A recombinant E1 and/or E2 and/or E1/E2 protein according to claim 81, further characterised in that said host cells are bacterial cells.

94. (new) A recombinant E1 and/or E2 and/or E1/E2 protein according to claim 81, further characterised in that said host cells are fungal cells.--

REMARKS

Reconsideration is requested.


The specification has been amended to include the drawing sheets required by the Notice dated October 30, 2001 (copy attached). The claims have been amended, without prejudice, to advance prosecution.

Ma rtens et al.
Serial No. 09/899,303

An early and favorable Action on the merits is requested.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: 
B. J. Sadoff
Reg. No. 36,663

BJS:eaw
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

09/899,303

MARKED UP SPECIFICATION

Page 36, amend the paragraph spanning lines 23-29 as follows:

Figure 21: [Nucleic acid sequences] Figures 21A-L provide nucleic acid sequences of the present invention. The nucleic acid sequences encoding an E1 or E2 protein according to the present invention may be translated (SEQ ID NO 3 to 13, 21-31, 35 and 41-49 are translated in a reading frame starting from residue number 1, SEQ ID NO:37-39 are translated in a reading frame starting from residue number 2), into the amino acid sequences of the respective E1 or E2 proteins as shown in the sequence listing.

Page 38, amend the paragraph spanning lines 32-35 as follows:

[Figure 35A] Figures 35A-1 to 35A-8: Antibody levels to the different HCV antigens (Core 1, Core 2, E2HCVR, NS3) for NR and LTR followed during treatment and over a period of 6 to 12 months after treatment determined by means of the LIAscan method. The average values are indicated by the curves with the open squares.

Page 39, delete the paragraph spanning lines 1-4, and insert the following therefor:

--[Figure 35B] Figures 35B-1 to 35B-8: Antibody levels to the different HCV antigens (NS4, NS5, E1 and E2) for NR and LTR followed during treatment and over a period of 6 to 12 months after treatment determined by means of the LIAscan method. The [avergae]

average [vallues] values are indicated by the curve with the open squares.--

Page 39, amend the paragraph spanning lines 6-7 as follows:

[Figure 36] Figures 36A and 36B: Average E1 antibody (E1Ab) and E2 antibody (E2Ab) levels in the LTR and NR groups.

Page 39, amend the paragraph spanning lines 8 and 9 as follows:

[Figure 37] Figures 36A-D: Averages E1 antibody (E1Ab) levels for non-responders (NR) and long term responders (LTR) for type 1b and type 3a.

09/899,303 - 121204